YIDU TECH (02158) first profitable annual report far exceeds expectations: profit of 78.77 million yuan for the 2026 fiscal year, operating cash flow turns positive in the second half of the year.

This morning, the leading Chinese AI healthcare company YIDU TECH (02158) held a performance conference to interpret its annual performance report for the fiscal year ending March 31, 2026 ("2026 fiscal year"). During the reporting period, the company achieved annual profitability for the first time, with annual profits reaching RMB 78.766 million, exceeding the upper limit of the profit forecast net profit range of RMB 55 to 70 million; net profit attributable to the parent company reached RMB 72.709 million, about 30% higher than the upper limit of the forecast corresponding to the net profit attributable to the parent company of RMB 56 million. The company's total revenue for the year increased by 14.6% year-on-year to reach RMB 820 million, and the adjusted EBITDA increased by over 4.6 times year-on-year to reach RMB 220 million. The quality of profitability has improved synchronously, with the overall gross profit margin further increasing from 33.5% in the same period last year to 36.4%. The net cash flow from operating activities turned positive in the second half of the year, recording RMB 29.3 million, indicating that the profit capability has entered an upward channel. In terms of growth momentum, the core sectors showed strong performance in new orders. The AI for Medical sector saw a 22.3% year-on-year increase in new orders, while the AI for Life Sciences sector saw a 42% year-on-year increase in new orders, providing clear visibility for future revenue growth. YIDU TECH Co-founder and CEO Xu Jiming said at the meeting that the 2026 fiscal year is an important node for the company to transition from long-term capacity building to commercial realization, with the same smart base continuing to release value in multiple scenarios such as medical, pharmaceutical, insurance, and patients: productization upgrades at the hospital end are steadily advancing, high-value orders at the pharmaceutical end continue to be released, and the health management sector maintains rapid growth. The company will continue to focus on high-value medical scenarios, pushing AI capabilities from project delivery towards platformization, productization, and scaled replication along the path of top hospitals, key specialties, and renowned experts. YIDU TECH Executive Director and CFO Feng Xiaoying stated that the company's first annual profitability was not dependent on one-off factors, but rather the result of a combination of business structure optimization, gross margin improvement, cost efficiency enhancement, and operational leverage release. With the net cash flow from operating activities turning positive in the second half of the year, the solid and sustainable quality of profitability has been further verified. Looking ahead, the company will continue to prudently allocate capital, focusing resources on disease areas and core customers that can generate long-term compound effects, and provide continuous, verifiable performance to reward shareholders' trust. Strength of YiduCore enhanced, continuous improvement of medical AI infrastructure attributes In terms of core technological barriers, YiduCore, as YIDU TECH's medical AI infrastructure built for the entire medical industry chain, is not a single model but a set of intelligent bases that integrate data governance platforms, medical knowledge systems, disease models, large model capabilities in medical vertical fields, and real-scene application frameworks. The medical field has extremely high requirements for professionalism, rigor, and safety, and the industry's core competitive strength is not limited to model parameters or general interactive capabilities, but in whether it can deeply understand disease development rules, fit clinical diagnosis and treatment logic, and adapt to real medical workflow processes. Based on this principle, the YiduCore, created to deeply root in medical practice with a focus on real disease evolution and clinical decision-making pathways. As of March 31, 2026, YiduCore has processed and analyzed nearly 9 billion authorized real-world medical records, and based on high-quality medical data processing capabilities and disease understanding formed by compliant authorization and standardized governance, it is the key factor determining the boundaries of medical AI capabilities and an important foundation for the company to build long-term competitive advantage. At the knowledge system level, YIDU TECH's specialized disease database covers hundreds of diseases, the disease knowledge map covers known diseases, and supports the construction of 21 specialized disease data sets. With the disease knowledge map, medical semantic understanding capabilities, and scene-oriented model training capabilities accumulated in more than ten years of deep cultivation in real medical world scenarios, YiduCore has formed a "data-driven algorithm, algorithm-powered scene, scene feeding data" flywheel, becoming the core engine for the company to output intelligent capabilities in the entire medical scenario. Three major businesses synergistically grow, AI drives structural upgrades During the reporting period, the three major business sectors achieved synchronized growth with the continuous empowerment of AI capabilities, and YiduCore's continuously reusing value as a unified medical AI base across scenarios was realized. AI for Medical (big data platforms and solutions) is the company's core pillar business, providing data-driven solutions for healthcare institutions and regulatory agencies at all levels. This fiscal year, this sector's revenue reached RMB 3.8 billion, a 10.2% year-on-year increase. As of the end of the reporting period, the company has served 133 top domestic hospitals, 54 regulatory agencies, and policymakers, with a hospital network covering over 12,000 medical institutions. During the reporting period, the company won multiple provincial key projects, including the Hainan Province comprehensive regional infectious disease monitoring and warning emergency command information platform, the Hainan Smart Health Island project, and undertook in-depth participation in the construction of national artificial intelligence application pilot bases in Beijing, Henan, and other regions to fully promote regional healthcare intelligence transformation. Additionally, with the launch of AI middleware 3.0, Copilot 2.0, Yidu Smart Loop, and Yidu Smart Management, the operational efficiency of the sector has significantly improved, with gross profit margins rising from 29.7% in the previous fiscal year to 39.7% in the reporting period, further strengthening its core competitiveness. AI for Life Sciences (solutions for life sciences) focuses on intelligent services throughout the pharmaceutical lifecycle, with the sector's revenue reaching RMB 2.7 billion this fiscal year, a 9.4% year-on-year growth, demonstrating strong business resilience. During the reporting period, the company continued to focus on a high-quality customer base, with 17 of the top 20 multinational pharmaceutical companies as clients; in clinical research, the company has participated in or completed over 516 clinical research projects, including trials initiated by pharmaceutical companies and researchers; with more than 320 prospective and retrospective real-world research projects. AI for Care (health management platforms and solutions) sector revenue reached RMB 1.7 billion this fiscal year, a significant increase of 37.6% year-on-year. In the field of universal health coverage, the company has served as the main operating platform for "Shenzhen Huimin Bao" for four consecutive years, and as the main operating platform for "Beijing Universal Health Bao" for five consecutive years, with Shenzhen Huimin Bao having a continuous annual insured population of over 6 million for three years, and Beijing Universal Health Bao accumulating over 19 million insured person-times. Additionally, the company actively penetrated the grassroots medical market, implementing digital diabetes therapy in 105 core medical institutions in five cities and counties including Sanya, Qionghai, Wanning, and Lingshui, effectively improving the blood sugar control rate of local patients and extending to more regions such as Shanxi and Tianjin. During the reporting period, the number of active users who completed at least one transaction on the health management platform exceeded 22 million. With the first annual profitability achieved in the 2026 fiscal year, YIDU TECH has entered a key stage of transitioning from the "continuous investment period" to the "scale realization period." The company believes that the medical AI industry is moving from technical validation towards commercial closure, with its core competitive strength shifting from single-point application capabilities to platformization, systematization, and cross-scenario reuse capabilities. In the future, YIDU TECH will continue to use YiduCore as the core to drive deep integration of AI capabilities in the entire medical institution, life sciences, and health management chain, accelerate the construction of a "data-algorithm-scenario" closed-loop system, continue to strengthen medical AI infrastructure capabilities, and achieve larger-scale commercial expansion within multiple ecosystems such as medical, pharmaceutical, insurance, and patients.